

CELL THERAPEUTICS INC  
Form 8-K  
June 24, 2008

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**  
**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of Report: (Date of earliest event reported): June 19, 2008

**CELL THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Washington**  
(State or other jurisdiction of  
incorporation or organization)

**001-12465**  
(Commission File Number)

**91-1533912**  
(I.R.S. Employer

Identification Number)

**501 Elliott Avenue West, Suite 400**

**Seattle, Washington 98119**

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

**Not applicable**

(Former name or former address, if changed since last report).

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Edgar Filing: CELL THERAPEUTICS INC - Form 8-K

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Section 5 Corporate Governance and Management**

**Item 5.03. Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On June 19, 2008, the Company filed Amended and Restated Articles of Incorporation (the Articles of Incorporation ) reflecting an increase in the authorized shares of the Company, an increase in the authorized common shares of the Company and a reduction in the quorum requirement for shareholder meetings from a majority of all shares entitled to vote to one-third of all shares entitled to vote. These amendments were approved by the Company's shareholders at the special meeting in lieu of annual meeting of the shareholders held at the Company's headquarters on June 19, 2008. The Company now has authorized 410,000,000 shares of capital stock, of which 400,000,000 are authorized as common stock of the Company. The Articles of Incorporation, which were effective as of June 19, 2008, are attached to this Form 8-K as Exhibit 3.1.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

The following exhibits are attached with this report on Form 8-K:

3.1 Amended and Restated Articles of Incorporation of the Corporation

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CELL THERAPEUTICS, INC.

Date: June 24, 2008

By: /s/ Louis A. Bianco  
Louis A. Bianco  
Executive Vice President, Finance and Administration

-2-

**EXHIBIT INDEX**

**Exhibit  
Number**

3.1 Amended and Restated Articles of Incorporation of the Corporation